Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer

This study has been terminated.

Sponsor:

Collaborator:

National Cancer Institute (NCI)

Information provided by:

Gynecologic Oncology Group

ClinicalTrials.gov Identifier:

NCT00002478

First received: November 1, 1999

Last updated: June 7, 2013

Last verified: November 2000

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been terminated.
Estimated Study Completion Date:	No date given
Primary Completion Date:	October 2003 (Final data collection date for primary outcome measure)

Publications:

Rose PG, Blessing JA, Buller RE, Mannel RS, Webster KD. Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2003 May;89(2):267-70.

Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998 Feb;16(2):405-10.

Kudelka A, ed.: A phase II study of prolonged oral VP-16 in women with refractoy epithelial ovarian carcinoma. [Abstract] Proceedings of the American Society of Clinical Oncology 13: A-888, 276, 1994.

To Top